Search
-
Ipsos Healthcare Launches MS Patient Community Panel
Ipsos Healthcare, the global healthcare business of Ipsos, has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel. This latest offer is part of the Ipsos Healthcare Global Patient Centre of Excellence, launched in 2018.
-
[EVENT] Intellus Summit 2018
Ipsos is delighted to be exhibiting at the healthcare industry’s biggest insights and analytics conference.
-
[EVENT] IIeX Health
March 27 - Ipsos is proud to be a silver sponsor of this year’s IIeX Health Summit which promises to share game-changing ideas to drive the healthcare and pharma industry forward.
-
Global perspectives on sector reputations
Which industries are facing the greatest reputation challenges at the moment?
-
Ipsos Healthcare Expands Syndicated Real World Evidence Offer in China
Ipsos Healthcare has extended its syndicated Psoriasis and IBD Therapy Monitors into China. It will also re-launch the Lupus Therapy Monitor in China due to increased client demand
-
Most Canadians Expect Companies to Support Causes and Make a Profit
New Ipsos study reveals how Canadians feel toward cause marketing. Strong cause marketing programs and not-for-profit partnerships are more necessary than ever for corporations.
-
Ipsos Launches Syndicated Social Listening in Healthcare
Deployed successfully, social listening can accelerate insight generation from any kind of text data: web forums, social media sites, survey verbatims, internal data, and much more.
-
Brexit and the UK Pharma Industry
The ‘In’ and ‘Out’ campaigns are now intensifying, but ‘Brexit’ has been a constant topic of conversation since the referendum date was announced 3 months ago. A British exit could have widespread repercussions for many sectors within the UK economy, especially in highly regulated and controlled industries such as pharmaceuticals.
-
Who Will Win the Race to Treat NASH?
Non-alcoholic Steatohepatitis, or NASH, is a liver disease characterized by rising prevalence, low diagnosis and a lack of therapies approved for treatment. All of these factors combine to make NASH a priority for the healthcare industry – and, potentially, a multi-billion-dollar market. Accordingly, the race is now on among several pharma companies to develop the first effective pharmacotherapy to treat NASH.